Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$19.03
0.442.37%
At close: -
$19.03
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
RXO Analyst Ratings and Price Targets | NYSE:RXO | Benzinga
RXO Inc has a consensus price target of $24.95 based on the ratings of 23 analysts. The high is $33 issued by Citigroup on November 12, 2024. The low is $12 issued by Susquehanna on November 12, 2024. The 3 most-recent analyst ratings were released by Truist Securities, Goldman Sachs, and Stifel on March 13, 2025, February 6, 2025, and February 6, 2025, respectively. With an average price target of $24 between Truist Securities, Goldman Sachs, and Stifel, there's an implied 26.12% upside for RXO Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Goldman Sachs
Stifel
Morgan Stanley
Barclays
1calculated from analyst ratings
Analyst Ratings for RXO
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/13/2025 | Buy Now | 26.12% | Truist Securities | Lucas Servera51% | → $24 | Initiates | → Buy | Get Alert |
| 02/06/2025 | Buy Now | 26.12% | Goldman Sachs | Jordan Alliger67% | $28 → $24 | Maintains | Neutral | Get Alert |
| 02/06/2025 | Buy Now | 26.12% | Stifel | J. Bruce Chan44% | $27 → $24 | Maintains | Hold | Get Alert |
| 02/06/2025 | Buy Now | 31.37% | Morgan Stanley | Ravi Shanker58% | $27 → $25 | Maintains | Equal-Weight | Get Alert |
| 01/23/2025 | Buy Now | 41.88% | Stifel | J. Bruce Chan44% | $26 → $27 | Maintains | Hold | Get Alert |
| 01/17/2025 | Buy Now | 57.65% | Barclays | Brandon Oglenski61% | $32 → $30 | Maintains | Overweight | Get Alert |
| 01/15/2025 | Buy Now | — | Benchmark | Christopher Kuhn53% | — | Reiterates | Hold → Hold | Get Alert |
| 01/10/2025 | Buy Now | 57.65% | Jefferies | Stephanie Moore56% | $33 → $30 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 47.14% | Wells Fargo | Christian Wetherbee73% | $31 → $28 | Maintains | Equal-Weight | Get Alert |
| 11/18/2024 | Buy Now | 52.39% | Goldman Sachs | Jordan Alliger67% | → $29 | Reinstates | → Neutral | Get Alert |
| 11/12/2024 | Buy Now | -36.94% | Susquehanna | Bascome Majors57% | $16 → $12 | Maintains | Negative | Get Alert |
| 11/12/2024 | Buy Now | 73.41% | Citigroup | Ariel Rosa67% | $33 → $33 | Downgrade | Buy → Neutral | Get Alert |
| 11/11/2024 | Buy Now | 62.9% | Wells Fargo | Allison Poliniak71% | → $31 | Reinstates | Equal-Weight → Equal-Weight | Get Alert |
| 10/15/2024 | Buy Now | — | Benchmark | Christopher Kuhn70% | — | Reiterates | → Hold | Get Alert |
| 10/09/2024 | Buy Now | 73.41% | Citigroup | Ariel Rosa67% | → $33 | Initiates | → Buy | Get Alert |
| 09/26/2024 | Buy Now | -15.92% | Susquehanna | Bascome Majors57% | $20 → $16 | Maintains | Negative | Get Alert |
| 09/17/2024 | Buy Now | 62.9% | Oppenheimer | Scott Schneeberger65% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 5.1% | Susquehanna | Bascome Majors57% | $14 → $20 | Maintains | Negative | Get Alert |
| 08/13/2024 | Buy Now | 62.9% | Jefferies | Stephanie Moore56% | $33 → $31 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | — | Benchmark | Christopher Kuhn70% | — | Reiterates | → Hold | Get Alert |
| 08/12/2024 | Buy Now | 36.63% | Morgan Stanley | Ravi Shanker58% | $19 → $26 | Maintains | Equal-Weight | Get Alert |
| 08/08/2024 | Buy Now | 47.14% | TD Cowen | Jason Seidl54% | $23 → $28 | Maintains | Hold | Get Alert |
| 08/08/2024 | Buy Now | 36.63% | JP Morgan | Brian Ossenbeck65% | $25 → $26 | Maintains | Underweight | Get Alert |
| 08/08/2024 | Buy Now | 62.9% | Oppenheimer | Scott Schneeberger65% | $22 → $31 | Maintains | Outperform | Get Alert |
| 08/08/2024 | Buy Now | 62.9% | UBS | Joseph Parkhill75% | $22 → $31 | Maintains | Neutral | Get Alert |
| 07/16/2024 | Buy Now | 57.65% | Barclays | Brandon Oglenski61% | $24 → $30 | Maintains | Overweight | Get Alert |
| 07/09/2024 | Buy Now | 31.37% | JP Morgan | Brian Ossenbeck65% | $16 → $25 | Maintains | Underweight | Get Alert |
| 06/12/2024 | Buy Now | — | Benchmark | Christopher Kuhn70% | — | Reiterates | → Hold | Get Alert |
| 05/15/2024 | Buy Now | — | Raymond James | Felix Boeschen71% | — | Reinstates | → Market Perform | Get Alert |
| 05/06/2024 | Buy Now | 15.61% | Stephens & Co. | Daniel Imbro67% | $22 → $22 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 04/19/2024 | Buy Now | — | Benchmark | Christopher Kuhn70% | — | Reiterates | → Hold | Get Alert |
| 03/26/2024 | Buy Now | -15.92% | Susquehanna | Bascome Majors57% | $15 → $16 | Maintains | Negative | Get Alert |
| 03/25/2024 | Buy Now | -15.92% | Susquehanna | Bascome Majors57% | $15 → $16 | Maintains | Negative | Get Alert |
| 02/13/2024 | Buy Now | 15.61% | Oppenheimer | Scott Schneeberger65% | $23 → $22 | Maintains | Outperform | Get Alert |
| 02/09/2024 | Buy Now | -21.18% | Susquehanna | Bascome Majors57% | $18 → $15 | Maintains | Negative | Get Alert |
| 02/08/2024 | Buy Now | 15.61% | B of A Securities | Ken Hoexter63% | $25 → $22 | Downgrade | Buy → Neutral | Get Alert |
| 01/10/2024 | Buy Now | 15.61% | Stifel | J. Bruce Chan44% | $20 → $22 | Maintains | Hold | Get Alert |
| 01/10/2024 | Buy Now | 20.86% | Vertical Research | Jeffrey Kauffman63% | → $23 | Downgrade | Buy → Hold | Get Alert |
| 10/16/2023 | Buy Now | -10.67% | Stifel | J. Bruce Chan44% | $19 → $17 | Maintains | Hold | Get Alert |
| 10/11/2023 | Buy Now | -15.92% | JP Morgan | Brian Ossenbeck65% | $17 → $16 | Downgrade | Neutral → Underweight | Get Alert |
| 10/03/2023 | Buy Now | -31.69% | Susquehanna | Bascome Majors57% | $14 → $13 | Maintains | Negative | Get Alert |
| 10/02/2023 | Buy Now | -5.41% | Morgan Stanley | Ravi Shanker58% | $20 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/31/2023 | Buy Now | -26.43% | Susquehanna | Bascome Majors57% | $19 → $14 | Downgrade | Neutral → Negative | Get Alert |
| 08/07/2023 | Buy Now | 26.12% | Oppenheimer | Scott Schneeberger65% | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | Buy Now | 5.1% | Morgan Stanley | Ravi Shanker58% | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | -0.16% | Stephens & Co. | Jack Atkins64% | $23 → $19 | Maintains | Equal-Weight | Get Alert |
| 07/12/2023 | Buy Now | -0.16% | Wolfe Research | Scott Group59% | → $19 | Downgrade | Peer Perform → Underperform | Get Alert |
| 07/06/2023 | Buy Now | 5.1% | Morgan Stanley | Ravi Shanker58% | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/09/2023 | Buy Now | 5.1% | Susquehanna | Bascome Majors57% | → $20 | Initiates | → Neutral | Get Alert |
| 05/24/2023 | Buy Now | 41.88% | Barclays | Brandon Oglenski61% | → $27 | Initiates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 10.35% | Wells Fargo | Allison Poliniak71% | $22 → $21 | Maintains | Equal-Weight | Get Alert |
| 04/04/2023 | Buy Now | — | Benchmark | Christopher Kuhn70% | — | Initiates | → Hold | Get Alert |
| 02/27/2023 | Buy Now | 15.61% | Cowen & Co. | Jason Seidl54% | → $22 | Initiates | → Market Perform | Get Alert |
| 02/09/2023 | Buy Now | 20.86% | UBS | Joseph Parkhill75% | $20 → $23 | Maintains | Neutral | Get Alert |
| 02/09/2023 | Buy Now | 15.61% | Goldman Sachs | Jordan Alliger67% | $20 → $22 | Maintains | Neutral | Get Alert |
| 02/09/2023 | Buy Now | 26.12% | Oppenheimer | Scott Schneeberger65% | $21 → $24 | Maintains | Outperform | Get Alert |
| 02/08/2023 | Buy Now | 5.1% | Stephens & Co. | Jack Atkins64% | → $20 | Maintains | Equal-Weight | Get Alert |
| 01/11/2023 | Buy Now | -10.67% | Stifel | J. Bruce Chan44% | $20 → $17 | Downgrade | Buy → Hold | Get Alert |
| 01/09/2023 | Buy Now | -0.16% | JP Morgan | Brian Ossenbeck65% | → $19 | Initiates | → Neutral | Get Alert |
| 12/20/2022 | Buy Now | -5.41% | Wells Fargo | Allison Poliniak71% | → $18 | Initiates | → Equal-Weight | Get Alert |
| 12/09/2022 | Buy Now | 5.1% | UBS | Thomas Wadewitz71% | → $20 | Initiates | → Neutral | Get Alert |
| 12/09/2022 | Buy Now | 5.1% | Morgan Stanley | Ravi Shanker58% | → $20 | Initiates | → Equal-Weight | Get Alert |
| 12/06/2022 | Buy Now | 31.37% | Jefferies | Stephanie Moore56% | → $25 | Initiates | → Buy | Get Alert |
| 12/05/2022 | Buy Now | — | Raymond James | Felix Boeschen71% | — | Initiates | → Market Perform | Get Alert |
| 11/30/2022 | Buy Now | 15.61% | B of A Securities | Ken Hoexter63% | → $22 | Initiates | → Buy | Get Alert |
| 11/22/2022 | Buy Now | 10.35% | Oppenheimer | Scott Schneeberger65% | → $21 | Initiates | → Outperform | Get Alert |
| 11/22/2022 | Buy Now | 5.1% | Goldman Sachs | Jordan Alliger67% | → $20 | Initiates | → Neutral | Get Alert |
| 11/21/2022 | Buy Now | 41.88% | Vertical Research | Jeffrey Kauffman63% | → $27 | Initiates | → Buy | Get Alert |
| 11/10/2022 | Buy Now | — | Wolfe Research | Scott Group59% | — | Initiates | → Peer Perform | Get Alert |
| 11/04/2022 | Buy Now | 5.1% | Stifel | J. Bruce Chan44% | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for RXO (RXO) stock?
The latest price target for RXO (NYSE:RXO) was reported by Truist Securities on March 13, 2025. The analyst firm set a price target for $24.00 expecting RXO to rise to within 12 months (a possible 26.12% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RXO (RXO)?
The latest analyst rating for RXO (NYSE:RXO) was provided by Truist Securities, and RXO initiated their buy rating.
When was the last upgrade for RXO (RXO)?
There is no last upgrade for RXO
When was the last downgrade for RXO (RXO)?
The last downgrade for RXO Inc happened on November 12, 2024 when Citigroup changed their price target from $33 to $33 for RXO Inc.
When is the next analyst rating going to be posted or updated for RXO (RXO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RXO, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RXO was filed on March 13, 2025 so you should expect the next rating to be made available sometime around March 13, 2026.
Is the Analyst Rating RXO (RXO) correct?
While ratings are subjective and will change, the latest RXO (RXO) rating was a initiated with a price target of $0.00 to $24.00. The current price RXO (RXO) is trading at is $19.03, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.